

# Olivier Lambotte

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9300614/publications.pdf>

Version: 2024-02-01

97  
papers

10,207  
citations

101543

36  
h-index

42399

92  
g-index

100  
all docs

100  
docs citations

100  
times ranked

13365  
citing authors

#	ARTICLE	IF	CITATIONS
1	Delivering adapted physical activity by videoconference to patients with fatigue under immune checkpoint inhibitors: Lessons learned from the PACTIME-FEAS feasibility study. <i>Journal of Telemedicine and Telecare</i> , 2023, 29, 716-724.	2.7	7
2	Anti-programmed death ligand 1 immunotherapies in cancer patients with pre-existing systemic sclerosis: A postmarketed phase IV safety assessment study. <i>European Journal of Cancer</i> , 2022, 160, 134-139.	2.8	10
3	Expansion of Immature Neutrophils During SIV Infection Is Associated With Their Capacity to Modulate T-Cell Function. <i>Frontiers in Immunology</i> , 2022, 13, 781356.	4.8	7
4	The letter responds to comment on: Anti-PD(L)1 immunotherapies in patients with cancer and with pre-existing systemic sclerosis: a post-marketed safety assessment study. <i>European Journal of Cancer</i> , 2022, 165, 208-209.	2.8	0
5	Reprogramming dysfunctional CD8+ T cells to promote properties associated with natural HIV control. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	15
6	Lack of association between the TNFAIP3 rs2230926 variant and rheumatoid arthritis-associated lymphoma. <i>Joint Bone Spine</i> , 2022, 89, 105390.	1.6	1
7	Detection of SARS-CoV-2 in subcutaneous fat but not visceral fat, and the disruption of fat lymphocyte homeostasis in both fat tissues in the macaque. <i>Communications Biology</i> , 2022, 5, .	4.4	7
8	EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 36-48.	0.9	153
9	Severe ulcerative gastrointestinal toxicity following ibrutinib therapy: two case studies. <i>Leukemia and Lymphoma</i> , 2021, 62, 984-987.	1.3	2
10	Clinical spectrum, outcome and management of immune thrombocytopenia associated with myelodysplastic syndromes and chronic myelomonocytic leukemia. <i>Haematologica</i> , 2021, 106, 1414-1422.	3.5	17
11	Severe IgA-mediated autoimmune hemolytic anemia triggered by SARS-CoV-2 infection. <i>Leukemia and Lymphoma</i> , 2021, 62, 2037-2039.	1.3	3
12	Severe anti-PD1-related meningoencephalomyelitis successfully treated with anti-integrin $\alpha 4$ therapy. <i>European Journal of Cancer</i> , 2021, 145, 230-233.	2.8	6
13	Use of immune checkpoint inhibitors in cancer patients with pre-existing sarcoidosis. <i>Immunotherapy</i> , 2021, 13, 465-475.	2.0	9
14	Long-term impact of immunotherapy on quality of life of surviving patients: A multi-dimensional descriptive clinical study. <i>European Journal of Cancer</i> , 2021, 148, 211-214.	2.8	4
15	CXCR3 and CXCR5 are highly expressed in HIV-specific CD8 central memory T cells from infected patients. <i>European Journal of Immunology</i> , 2021, 51, 2040-2050.	2.9	2
16	Antiretroviral therapy for HIV controllers: Reasons for initiation and outcomes in the French ANRS-CO21 CODEX cohort. <i>EClinicalMedicine</i> , 2021, 37, 100963.	7.1	5
17	Immune checkpoint inhibitor-associated sarcoidosis: A usually benign disease that does not require immunotherapy discontinuation. <i>European Journal of Cancer</i> , 2021, 158, 208-216.	2.8	33
18	Leukocyte Immunoglobulin-Like Receptors in Regulating the Immune Response in Infectious Diseases: A Window of Opportunity to Pathogen Persistence and a Sound Target in Therapeutics. <i>Frontiers in Immunology</i> , 2021, 12, 717998.	4.8	29

#	ARTICLE	IF	CITATIONS
19	Elite and viremic HIV-1 controllers in West Africa. <i>Aids</i> , 2021, Publish Ahead of Print, 29-38.	2.2	0
20	Outcomes of patients with cancer and sarcoid-like granulomatosis associated with immune checkpoint inhibitors: A caseâ€“control study. <i>European Journal of Cancer</i> , 2021, 156, 46-59.	2.8	16
21	Neurological complications induced by immune checkpoint inhibitors: a comprehensive descriptive case-series unravelling high risk of long-term sequelae. <i>Brain Communications</i> , 2021, 3, fcab220.	3.3	16
22	Absence of significant clinical benefit for a systematic routine creatine phosphokinase measurement in asymptomatic patients treated with anti-programmed death protein (ligand) 1 immune checkpoint inhibitor to screen cardiac or neuromuscular immune-related toxicities. <i>European Journal of Cancer</i> , 2021, 157, 383-390.	2.8	6
23	The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry. <i>European Journal of Cancer</i> , 2021, 158, 217-224.	2.8	35
24	Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021. <i>Nature Medicine</i> , 2021, 27, 2085-2098.	30.7	146
25	Mass Cytometry Reveals the Immaturity of Circulating Neutrophils during SIV Infection. <i>Journal of Innate Immunity</i> , 2020, 12, 170-181.	3.8	12
26	Systemic lupus erythematosus associated with thymoma: A fifteen-year observational study in France. <i>Autoimmunity Reviews</i> , 2020, 19, 102464.	5.8	5
27	Optimal Maturation of the SIV-Specific CD8+ T Cell Response after Primary Infection Is Associated with Natural Control of SIV: ANRS SIC Study. <i>Cell Reports</i> , 2020, 32, 108174.	6.4	12
28	How to manage patients with corticosteroids in oncology in the era of immunotherapy?. <i>European Journal of Cancer</i> , 2020, 141, 239-251.	2.8	52
29	Infectious complications in patients treated with immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2020, 141, 137-142.	2.8	24
30	Immune-related adverse events of checkpoint inhibitors. <i>Nature Reviews Disease Primers</i> , 2020, 6, 38.	30.5	684
31	Letter responds to the comment in â€“immune thrombocytopenia of haematological immune-related adverse events in cancer immunotherapy: Most and mightyâ€™. <i>European Journal of Cancer</i> , 2020, 134, 60-61.	2.8	0
32	Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities. <i>Autoimmunity Reviews</i> , 2020, 19, 102586.	5.8	80
33	Management of immune-related adverse events associated with immune checkpoint inhibitors in cancer patients: a patient-centred approach. <i>Internal and Emergency Medicine</i> , 2020, 15, 587-598.	2.0	16
34	The 2016â€“2019 ImmunoTOX assessment board report of collaborative management of immune-related adverse events, an observational clinical study. <i>European Journal of Cancer</i> , 2020, 130, 39-50.	2.8	37
35	Haemophagocytic lymphohistiocytosis associated with immune checkpoint inhibitors: a descriptive case study and literature review. <i>British Journal of Haematology</i> , 2020, 189, 985-992.	2.5	27
36	Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study. <i>Arthritis and Rheumatology</i> , 2019, 71, 2100-2111.	5.6	202

#	ARTICLE	IF	CITATIONS
37	HIV controllers: to treat or not to treat? Is that the right question?. <i>Lancet HIV</i> ,the, 2019, 6, e878-e884.	4.7	13
38	HIV-1 Envelope Overcomes NLRP3-Mediated Inhibition of F-Actin Polymerization for Viral Entry. <i>Cell Reports</i> , 2019, 28, 3381-3394.e7.	6.4	28
39	Addressing immune-related adverse events of cancer immunotherapy: how prepared are rheumatologists?. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 860-862.	0.9	14
40	Cynomolgus macaque IL37 polymorphism and control of SIV infection. <i>Scientific Reports</i> , 2019, 9, 7981.	3.3	3
41	Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer. <i>JAMA Oncology</i> , 2019, 5, 1310.	7.1	268
42	Inherited Thrombotic Thrombocytopenic Purpura Revealed by Recurrent Strokes in a Male Adult: Case Report and Literature Review. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2019, 28, 1537-1539.	1.6	5
43	Prevalence and Clinical Patterns of Ocular Complications Associated With Anti-PD-1/PD-L1 Anticancer Immunotherapy. <i>American Journal of Ophthalmology</i> , 2019, 202, 109-117.	3.3	62
44	Cold agglutinin disease as a new immune-related adverse event associated with anti-PD-L1s and its treatment with rituximab. <i>European Journal of Cancer</i> , 2019, 110, 21-23.	2.8	10
45	Cardiovascular Events in the French ANRS HIV Controller Cohort. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 82, e32-e34.	2.1	9
46	Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study. , 2019, 7, 337.		75
47	Dynamics in HIV DNA levels over time in HIV controllers. <i>Journal of the International AIDS Society</i> , 2019, 22, e25221.	3.0	21
48	Reply to: "Acute liver failure due to immune-mediated hepatitis successfully managed with plasma exchange: New settings call for new treatment strategies". <i>Journal of Hepatology</i> , 2019, 70, 566-567.	3.7	2
49	Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study. <i>Lancet Haematology</i> ,the, 2019, 6, e48-e57.	4.6	195
50	Sicca/Sjögren's syndrome triggered by PD-1/PD-L1 checkpoint inhibitors. Data from the International ImmunoCancer Registry (ICIR). <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 118, 114-122.	0.8	19
51	Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. <i>Journal of Hepatology</i> , 2018, 68, 1181-1190.	3.7	372
52	Efficacy and safety of rituximab for systemic lupus erythematosus-associated immune cytopenias: A multicenter retrospective cohort study of 71 adults. <i>American Journal of Hematology</i> , 2018, 93, 424-429.	4.1	56
53	Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease. <i>European Journal of Cancer</i> , 2018, 91, 21-29.	2.8	222
54	Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1. <i>European Journal of Cancer</i> , 2018, 96, 91-104.	2.8	94

#	ARTICLE	IF	CITATIONS
55	Effect of CRP value on 18Fâ€“FDG PET vascular positivity in Takayasu arteritis: a systematic review and per-patient based meta-analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 575-581.	6.4	17
56	Reply to: â€œIncidence of grade 3â€“4 liver injury under immune checkpoints inhibitors: A retrospective studyâ€œ. <i>Journal of Hepatology</i> , 2018, 69, 1397-1398.	3.7	2
57	Reply to: â€œImmune-related hepatitis with immunotherapy: Are corticosteroids always needed?â€œ. <i>Journal of Hepatology</i> , 2018, 69, 550-551.	3.7	2
58	A high-resolution mass cytometry analysis reveals a delay of cytokines production after TLR4 or TLR7/8 engagements in HIV-1 infected humans. <i>Cytokine</i> , 2018, 111, 97-105.	3.2	9
59	Reply to: â€œMortality due to immunotherapy related hepatitisâ€œ. <i>Journal of Hepatology</i> , 2018, 69, 978-979.	3.7	0
60	International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus. <i>Autoimmunity Reviews</i> , 2017, 16, 650-657.	5.8	32
61	Immune-related bone marrow failure following anti-PD1 therapy. <i>European Journal of Cancer</i> , 2017, 80, 1-4.	2.8	36
62	A Subset of Extreme Human Immunodeficiency Virus (HIV) Controllers Is Characterized by a Small HIV Blood Reservoir and a Weak T-Cell Activation Level. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx064.	0.9	45
63	HIV-Specific B Cell Frequency Correlates with Neutralization Breadth in Patients Naturally Controlling HIV-Infection. <i>EBioMedicine</i> , 2017, 21, 158-169.	6.1	45
64	Late-occurring nivolumab-induced cryptogenic organising pneumonia mimicking lung progression in a patient with metastatic nonâ€“small cell lung cancer. <i>European Journal of Cancer</i> , 2017, 85, 155-157.	2.8	6
65	Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis. <i>European Journal of Cancer</i> , 2017, 82, 34-44.	2.8	146
66	Immune-related eosinophilia induced by anti-programmed death 1 or death-ligand 1 antibodies. <i>European Journal of Cancer</i> , 2017, 81, 135-137.	2.8	55
67	Detectable HIV-RNA in semen of HIV controllers. <i>PLoS ONE</i> , 2017, 12, e0183376.	2.5	8
68	Impact of CD4 and CD8 dynamics and viral rebounds on loss of virological control in HIV controllers. <i>PLoS ONE</i> , 2017, 12, e0173893.	2.5	30
69	Thymic Epithelial Tumor-Associated Cytopenia: A 10-Year Observational Study in France. <i>Journal of Thoracic Oncology</i> , 2016, 11, 391-399.	1.1	11
70	Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 473-486.	27.6	831
71	Characteristics, outcome, and response to therapy of multirefractory chronic immune thrombocytopenia. <i>Blood</i> , 2016, 128, 1625-1630.	1.4	78
72	Risk factors associated with intracranial hemorrhage in adults with immune thrombocytopenia: A study of 27 cases. <i>American Journal of Hematology</i> , 2016, 91, E499-E501.	4.1	20

#	ARTICLE	IF	CITATIONS
73	Cancers in elite controllers. <i>Aids</i> , 2016, 30, 1852-1855.	2.2	6
74	Disseminated intravascular coagulation following administration of sunitinib. <i>Molecular and Clinical Oncology</i> , 2016, 5, 121-123.	1.0	1
75	Two cases of immune thrombocytopenia associated with pembrolizumab. <i>European Journal of Cancer</i> , 2016, 54, 172-174.	2.8	52
76	Life-threatening Hughes-Stovin syndrome: The Yin and Yang of anticoagulation therapy. <i>Joint Bone Spine</i> , 2016, 83, 459-460.	1.6	5
77	Public T cell receptors confer high-avidity CD4 responses to HIV controllers. <i>Journal of Clinical Investigation</i> , 2016, 126, 2093-2108.	8.2	63
78	Adipose Tissue Is a Neglected Viral Reservoir and an Inflammatory Site during Chronic HIV and SIV Infection. <i>PLoS Pathogens</i> , 2015, 11, e1005153.	4.7	191
79	Polymorphisms of large effect explain the majority of the host genetic contribution to variation of HIV-1 virus load. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 14658-14663.	7.1	154
80	Immunologic and Virologic Progression in HIV Controllers: The Role of Viral "Blips" and Immune Activation in the ANRS CO21 CODEX Study. <i>PLoS ONE</i> , 2015, 10, e0131922.	2.5	50
81	Blunted Response to Combination Antiretroviral Therapy in HIV Elite Controllers: An International HIV Controller Collaboration. <i>PLoS ONE</i> , 2014, 9, e85516.	2.5	34
82	Successful Outcome of a Corticoid-dependent Henoch-Schönlein Purpura Adult with Rituximab. <i>Case Reports in Medicine</i> , 2014, 2014, 1-4.	0.7	25
83	Efficacy of Recombinant Human Interleukin 7 in a Patient With Severe Lymphopenia-Related Progressive Multifocal Leukoencephalopathy. <i>Open Forum Infectious Diseases</i> , 2014, 1, ofu074.	0.9	29
84	Both HLA-B*57 and Plasma HIV RNA Levels Contribute to the HIV-Specific CD8 <sup>+</sup> T Cell Response in HIV Controllers. <i>Journal of Virology</i> , 2014, 88, 176-187.	3.4	39
85	Development and Validation of the HScore, a Score for the Diagnosis of Reactive Hemophagocytic Syndrome. <i>Arthritis and Rheumatology</i> , 2014, 66, 2613-2620.	5.6	875
86	Autoimmune diseases in HIV-infected patients: 52 cases and literature review. <i>Autoimmunity Reviews</i> , 2014, 13, 850-857.	5.8	101
87	Reduction of death receptor 5 expression and apoptosis of CD4 <sup>+</sup> T cells from HIV controllers. <i>Clinical Immunology</i> , 2014, 155, 17-26.	3.2	7
88	Elevated IP10 levels are associated with immune activation and low CD4 <sup>+</sup> T-cell counts in HIV controller patients. <i>Aids</i> , 2014, 28, 467-476.	2.2	85
89	Natural history of HIV-control since seroconversion. <i>Aids</i> , 2013, 27, 2451-2460.	2.2	44
90	High Antibody-Dependent Cellular Cytotoxicity Responses Are Correlated with Strong CD8 T Cell Viral Suppressive Activity but Not with B57 Status in HIV-1 Elite Controllers. <i>PLoS ONE</i> , 2013, 8, e74855.	2.5	76

#	ARTICLE	IF	CITATIONS
91	CD4 Dynamics over a 15 Year-Period among HIV Controllers Enrolled in the ANRS French Observatory. PLoS ONE, 2011, 6, e18726.	2.5	52
92	Restriction of HIV-1 replication in macrophages and CD4+ T cells from HIV controllers. Blood, 2011, 118, 955-964.	1.4	107
93	Characteristics and Long-Term Outcome of 15 Episodes of Systemic Lupus Erythematosus-Associated Hemophagocytic Syndrome. Medicine (United States), 2006, 85, 169-182.	1.0	112
94	Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nature Medicine, 2006, 12, 1365-1371.	30.7	3,107
95	Pegylated interferon alpha-2a-associated life-threatening Evans' syndrome in a patient with chronic hepatitis C. Journal of Infection, 2005, 51, e113-e115.	3.3	18
96	HIV Controllers: A Homogeneous Group of HIV-1-Infected Patients with Spontaneous Control of Viral Replication. Clinical Infectious Diseases, 2005, 41, 1053-1056.	5.8	355
97	Efficacy of rituximab in refractory polymyositis. Journal of Rheumatology, 2005, 32, 1369-70.	2.0	91